Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

By sjmartinez • June 13, 2023

Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916. Epub ahead of print. PMID: 37308218.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, methotrexate, Publications, Rheumatology, tumor necrosis factor inhibitors

Get With the Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead

Tang AB, Lewsey SC, Yancy CW, Heidenreich PA, Greene SJ, Allen LA, Jessup M, Bolles M, Rutan C, Navar N, Thomas K, Fonarow GC. Get[...]

Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United States Federally Qualified Health Centers

Zhao MY, Aaronson MRM, Singh V, De Silva SR, Badiee J, May FP. Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United[...]

Validating the Sino-Nasal Outcome Test (SNOT-22) in comparison to the Sino-Nasal 5 Questionnaire (SN-5) in a pediatric population

Cheng MY, Rodriguez DR, Rubio A, Jackson NJ, West AN. Validating the Sino-Nasal Outcome Test (SNOT-22) in comparison to the Sino-Nasal 5 Questionnaire (SN-5) in[...]